Prognostic effects of SuPAR and Neopterin Levels on Patients with Lung Cancer

dc.contributor.author	Yalcin, S.
dc.contributor.author	Demir, M.E.
dc.contributor.author	Ozturk, R.
dc.contributor.author	Klllnç, A.Å.
dc.contributor.author	Suer, H.
dc.contributor.author	Karahan, I.
dc.date.accessioned	2021-12-21T08:40:49Z
dc.date.available	2021-12-21T08:40:49Z
dc.date.issued	2020
dc.identifier.issn	21954720
dc.identifier.uri	https://doi.org/10.1515/pteridines-2020-0017
dc.identifier.uri	http://dspace.yeniyuzyil.edu.tr:8080/xmlui/handle/20.500.12629/1210
dc.description.abstract	Background: Two unique biomarkers, soluble form of the urokinase-type plasminogen activator receptor (suPAR) and neopterin, play a crucial role in inflammatory processes. This study aimed to reveal whether it is possible to utilize these biomarkers in pre
dc.language.iso	English
dc.publisher	De Gruyter Open Ltd
dc.rights	All Open Access, Gold
dc.title	Prognostic effects of SuPAR and Neopterin Levels on Patients with Lung Cancer
dc.type	Article
dc.relation.journal	Pteridines
dc.identifier.issue	1
dc.identifier.startpage	136
dc.identifier.endpage	141
dc.identifier.volume	31
dc.identifier.doi	10.1515/pteridines-2020-0017
dc.relation.issue	1
dc.relation.volume	31

Bu öğenin dosyaları:

Dosyalar	Boyut	Biçim	Göster
Bu öğe ile ilişkili dosya yok.